Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Degarelix vs goserelin + bicalutamide for prostate volume reduction in prostate cancer
2008-008604-40Phase 3Completed
- Sponsor
- Ferring Pharmaceuticals
- Start
- Mar 2009
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in prostate cancer (PCa) comparing Degarelix with Goserelin + bicalutamide (2 arms). Primary endpoint: Mean percentage reduction in prostate volume at 12 weeks. Started Mar 2009; status: completed.
02
Drugs
degarelixgoserelinbicalutamide
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2008-008604-40.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-008604-40.